Metraipolis › archive › dc_d1bf9923b41d

The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of… — Europe PMC PMID:41059208

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41059208
DOI
10.3389/fphar.2025.1612921
License (as archived)
solo-consultazione
Archived
2026-11-09T19:55:39.369Z
SHA-256 of the archived text
6269ee5a493a1f1b707c742166b6f4d08565fbded139f5d508396783ba9726d2
Stable URL of this page
https://metraipolis.com/documento/dc_d1bf9923b41d

How to cite

The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of… — Europe PMC PMID:41059208 — Europe PMC (en), https://europepmc.org/article/MED/41059208 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d1bf9923b41d (Metraipolis archive dc_d1bf9923b41d, sha256 6269ee5a493a1f1b707c742166b6f4d08565fbded139f5d508396783ba9726d2)
BibTeX
@misc{dcd1bf9923b41d,
  title = {The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of… — Europe PMC PMID:41059208},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41059208},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d1bf9923b41d; sha256 6269ee5a493a1f1b707c742166b6f4d08565fbded139f5d508396783ba9726d2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41059208. Agents can read the archived copy with the MCP tool read_document.